Superworth

Integra Lifesciences price to book ratio IART

Market value divided by the book value of the company's net assets, since 2010.

Today, Oct 23, 2026
0.9×
10-year median
2.9×
Against its 10-year history
6th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.6× to 5.3×
Peer median
2.9×

Integra Lifesciences' price to book ratio is 0.9× as of Oct 23, 2026.

That is below its ten-year median of 2.9×, lower than on 94% of days in the last ten years.

Over that time it ranged from 0.6× in Jul 2025 to 5.3× in Jun 2018.

The median for 10 medical instruments and supplies stocks of a similar size is 2.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.9×0.7×1.5×
20250.9×0.6×1.3×
20241.1×0.9×2.2×
20232.2×1.7×2.9×
20222.7×2.1×3.6×
20213.5×3.3×4.2×
20203.9×2.3×4.0×
20193.6×2.8×3.9×
20182.8×2.8×5.3×
20174.1×1.9×4.9×
20161.9×1.7×4.1×
20153.4×2.6×3.4×
20142.6×2.1×2.8×
20132.7×1.8×2.8×
20122.0×1.3×2.2×
20111.6×1.5×3.1×
20102.8×2.3×3.0×

Against its peers

Companies in Medical - Instruments & Supplies nearest Integra Lifesciences' size, closest first, today.

CompanyPrice to book ratio
IARTIntegra Lifesciences0.9×
IRMDIradimed10.8×
STAAStaar Surgical3.1×
MOVMovado1.4×
BVSBioventus5.5×
CDRECadre3.7×
EYENational Vision1.6×
MDXGMimedx2.6×
TCMDTactile Systems Technology2.4×
LMATLemaitre Vascular4.6×
INSPInspire Medical Systems2.5×
Peer median2.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Integra Lifesciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.